Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Tafluprost significantly decreases central corneal thickness (CCT) in patients with open-angle glaucoma or ocular hypertension, with severe reductions (≥25 μm) reported in 3.8% to 14.8% of participants after more than 6 months of treatment.
• In comparison to latanoprostene bunod (LBN), tafluprost showed numerically less efficacy in intraocular pressure (IOP) reduction but was more effective than several beta-blockers (apraclonidine, betaxolol, brimonidine, brinzolamide, carteolol, dorzolamide, and timolol).
• The combination of tafluprost with topical non-steroidal anti-inflammatory drugs (NSAIDs) significantly enhances IOP lowering effects in glaucoma patients compared to prostaglandin analog (PGA) monotherapy.
• Specific safety comparisons between tafluprost and other prostaglandin analogues (PGAs) or beta-blockers were not provided in the reviewed studies.
• The studies primarily involved adult patients over 18 years old with open-angle glaucoma or ocular hypertension, highlighting that tafluprost showed more prominent effectiveness in reducing central corneal thickness (CCT) with prolonged use (more than 6 months) and that glaucoma patients receiving combination therapy with topical NSAIDs experienced enhanced IOP lowering effects compared to those on PGAs alone.